{
  "report_rows": [
    {
      "kpi": "FFO as Adjusted per share",
      "prediction": "BEAT",
      "answer": "pred ~$0.44 vs. cons $0.43",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Total same-store Cash Adjusted NOI growth",
      "prediction": "BEAT",
      "answer": "pred ~1.2% vs. cons 0.0%",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Lab total occupancy",
      "prediction": "IN-LINE",
      "answer": "pred ~78.3% vs. cons 78.0%",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "2026 FFO as Adjusted per share guidance",
      "prediction": "BETTER",
      "answer": "guide ~$1.73-$1.77 vs. cons $1.74 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Total same-store Cash Adjusted NOI growth guidance",
      "prediction": "BETTER",
      "answer": "guide ~0.0%-2.0% vs. cons 0.5% (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Year-end Lab total occupancy commentary",
      "prediction": "BETTER",
      "answer": "guide ~78.5% vs. cons 78.0% (4Q2026)",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": 2.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 3.5,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "A ~$0.44 quarterly FFO result versus $0.43 consensus plus a ~$1.75 midpoint versus $1.74 consensus supports modest 2027 estimate upside: lab occupancy improvement and stronger same-store NOI make the beat more durable than a one-quarter timing benefit.",
  "day5_confidence": "MEDIUM"
}